All of the above findings suggest that the loss of C9orf72 may act synergistically with a gain-of-toxicity mechanism in C9ALS/FTD pathogenesis and indicate that limiting SG hyperformation and enhancing SG removal may be feasible strategies for the treatment of C9ALS/FTD. This evidence concerns the gene C9orf72 and frontotemporal dementia.